Hansoh Pharmaceutical Group Company Limited

DB:3KY Stock Report

Market Cap: €13.1b

Hansoh Pharmaceutical Group Valuation

Is 3KY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3KY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3KY (€2.16) is trading below our estimate of fair value (€3.49)

Significantly Below Fair Value: 3KY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3KY?

Key metric: As 3KY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3KY. This is calculated by dividing 3KY's market cap by their current earnings.
What is 3KY's PE Ratio?
PE Ratio21.2x
EarningsCN¥4.71b
Market CapCN¥99.90b

Price to Earnings Ratio vs Peers

How does 3KY's PE Ratio compare to its peers?

The above table shows the PE ratio for 3KY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.5x
MRK Merck KGaA
22.3x11.1%€60.1b
DMP Dermapharm Holding
22.6x17.0%€2.0b
PSG PharmaSGP Holding
15.1x13.6%€283.0m
2FJ0 Pierrel
29.9xn/a€92.8m
3KY Hansoh Pharmaceutical Group
21.2x3.5%€106.5b

Price-To-Earnings vs Peers: 3KY is good value based on its Price-To-Earnings Ratio (21.2x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does 3KY's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
3KY 21.2xIndustry Avg. 19.3xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 3KY is expensive based on its Price-To-Earnings Ratio (21.2x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is 3KY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3KY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.2x
Fair PE Ratio17.1x

Price-To-Earnings vs Fair Ratio: 3KY is expensive based on its Price-To-Earnings Ratio (21.2x) compared to the estimated Fair Price-To-Earnings Ratio (17.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3KY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.16
€2.87
+33.0%
13.4%€3.61€2.15n/a20
Dec ’25€2.28
€2.83
+23.9%
13.1%€3.60€2.14n/a21
Nov ’25€2.02
€2.79
+38.3%
12.9%€3.57€2.13n/a21
Oct ’25€2.32
€2.70
+16.2%
11.1%€3.35€2.10n/a21
Sep ’25€2.28
€2.61
+14.6%
12.3%€3.32€2.09n/a21
Aug ’25€1.93
€2.38
+23.3%
13.8%€3.30€2.02n/a19
Jul ’25€1.86
€2.32
+24.8%
15.2%€3.31€1.78n/a18
Jun ’25€1.88
€2.27
+20.6%
15.7%€3.29€1.76n/a18
May ’25€2.08
€2.26
+8.6%
15.8%€3.33€1.76n/a19
Apr ’25€1.82
€2.14
+17.8%
16.1%€3.32€1.62n/a18
Mar ’25€1.60
€1.97
+23.1%
20.8%€2.97€1.32n/a19
Feb ’25€1.38
€1.98
+43.7%
20.7%€2.98€1.32n/a19
Jan ’25n/a
€1.91
0%
21.8%€2.96€1.31n/a19
Dec ’24n/a
€1.92
0%
21.8%€2.98€1.32€2.2819
Nov ’24€1.69
€1.87
+10.9%
23.5%€3.00€1.22€2.0219
Oct ’24€1.27
€1.87
+47.5%
23.2%€2.98€1.21€2.3219
Sep ’24€1.15
€1.94
+69.0%
23.3%€3.28€1.20€2.2819
Aug ’24€1.43
€2.02
+41.2%
18.3%€3.23€1.39€1.9319
Jul ’24€1.47
€2.04
+38.6%
17.0%€3.10€1.45€1.8619
Jun ’24€1.55
€2.12
+36.9%
17.1%€3.23€1.51€1.8819
May ’24€1.59
€2.12
+33.1%
17.3%€3.21€1.50€2.0818
Apr ’24€1.53
€2.15
+40.4%
17.7%€3.29€1.54€1.8216
Mar ’24€1.70
€2.36
+39.1%
19.1%€3.72€1.67€1.6015
Feb ’24€1.82
€2.38
+30.7%
20.2%€3.88€1.67€1.3815
Jan ’24€1.70
€2.63
+54.5%
38.7%€5.79€1.69n/a14
Dec ’23€1.75
€2.61
+49.0%
38.7%€5.75€1.68n/a14

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 07:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansoh Pharmaceutical Group Company Limited is covered by 32 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Bo LiBofA Global Research
Jin ZhangChina International Capital Corporation Limited